

**TENNESSEE GENERAL ASSEMBLY
FISCAL REVIEW COMMITTEE**



FISCAL NOTE

SB 109 - HB 635

March 23, 2009

SUMMARY OF BILL: Requires a pharmacist to notify a patient or his or her representative and the prescribing physician prior to the interchange of an immunosuppressive drug.

ESTIMATED FISCAL IMPACT:

Increase State Expenditures – Not Significant

Assumptions:

- Current law (Tenn. Code Ann. § 53-10-204) authorizes a prescriber to substitute a generic equivalent drug for the brand name unless the prescriber determines that it is medically necessary to have the brand name or that the generic equivalent is not available. The proposed legislation would add a requirement that the notification requirements be complied with in instances involving an immunosuppressive drug prior to prescribing a generic substitution.
- The Department of Health will not incur a significant increase in expenditures to provide notification and assistance to pharmacists in order to understand the notification requirements.
- The Department of Health will not incur a significant increase in complaints filed against pharmacists or pharmacies with the Board of Pharmacy. Any increase in expenditures will be not significant.
- There will not be a fiscal impact on the pharmacy benefits of the TennCare program.

CERTIFICATION:

This is to duly certify that the information contained herein is true and correct to the best of my knowledge.

A handwritten signature in cursive script, reading "James W. White".

James W. White, Executive Director

/kml

SB 109 - HB 635